GF Fund Management’s Vertex Pharmaceuticals VRTX Stock Holding History

GF Fund Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28.8M	Sell	64,591 -820	-1%	-$382K	0.48%	42
2025 Q4	$29.7M	Buy	65,411 +2,620	+4%	+$1.13M	0.51%	45
2025 Q3	$24.6M	Buy	62,791 +474	+0.8%	+$198K	0.45%	51
2025 Q2	$27.7M	Buy	62,317 +1,505	+2%	+$694K	0.56%	42
2025 Q1	$29.5M	Buy	60,812 +1,634	+3%	+$761K	0.69%	32
2024 Q4	$23.8M	Buy	+59,178	New	+$27.4M	0.52%	40

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

GF Fund Management's VRTX Position: Q1 2026 in Review

GF Fund Management reduced its Vertex Pharmaceuticals (VRTX) stake by 1.3% in Q1 2026, selling an estimated $382K and leaving 64,591 shares worth $28.8M. The position accounts for 0.48% of the portfolio, ranked #42.

GF Fund Management first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $29.7M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

GF Fund Management held 64,591 shares of Vertex Pharmaceuticals worth $28.8M as of Q1 2026.
GF Fund Management sold 820 Vertex Pharmaceuticals shares in Q1 2026, an estimated $382K.
Vertex Pharmaceuticals made up 0.48% of GF Fund Management's portfolio in Q1 2026, its #42 holding.
GF Fund Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
GF Fund Management's Vertex Pharmaceuticals position peaked at $29.7M in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.